DCGI approves Dr Reddy's request to conduct Phase 2, 3 clinical trials with Russia's Sputnik V COVD-19 vaccine

RDIF will also supply 100 million doses of Dr Reddy's after receiving Indian regulatory approval.

tech2 News Staff October 19, 2020 11:48:46 IST
DCGI approves Dr Reddy's request to conduct Phase 2, 3 clinical trials with Russia's Sputnik V COVD-19 vaccine

Dr Reddy's Laboratories to conduct Phase 2,3 clinical trials with Sputnik V vaccine

After being denied their request to conduct a phase three clinical trial with Russia's Sputnik V COVID-19 vaccine and asked to submit a new request, the Controller General of Medicines of India (DCGI) has given Dr Reddy's Laboratories its approval.

The big pharma will conduct Phase 2-3 clinical trials of the vaccine instead of jumping straight to Phase 3. The reason the first request was overturned was due to a lack of sufficient safety and efficacy data on the Russian vaccine.

GV Prasad, co-chairman and managing director of Dr Reddy's, said in a statement, “We are grateful for DCGI's scientific approach and support in the application process."

"Regulatory approval provides an opportunity to initiate clinical trials in India and further supply a safe and effective vaccine to combat the pandemic,” he added.

After the first application was evaluated by the Subject Expert Committee (SEC) on COVID-19 at Central Drugs Standard Control Organisation (CDSCO), the regulator said Dr Reddy's cannot directly conduct a phase 3 trial for the COVID-19 vaccine. This, since the sample size of early human trials for the vaccine carried out in Russia, was "small", and information of its safety and the immunogenic effect was insufficient for Indian subjects.

CDSCO had asked Dr Reddy’s to submit a revised application, which includes new protocols for both phase 2 and phase 3 human clinical trials instead of just phase 3. A PTI report states that the pharma giant was asked to submit additional information as well, but as to what was specified, it is unclear.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said in a statement, "We are delighted to be working with regulatory authorities in India and will provide data on the safety and immunogenicity of the vaccine from Phase 3 trials in Russia, in addition to data from clinical trials in India to facilitate successful Sputnik V trials in the country."

India, overlooked by Dr Reddy's will be conducting a multicenter, randomized controlled trial, which will include safety and immunogenicity trials. RDIF will also supply 100 million doses of Dr Reddy's after receiving Indian regulatory approval.

The on-going post-registration Sputnik V vaccine trials are being conducted in Russia on 40,000 volunteers as well as in Belarus, Venezuela and the United Arab Emirates.

Updated Date:

also read

Narendra Modi reviews India's COVID-19 vaccine strategy,  prioritisation of population groups
India

Narendra Modi reviews India's COVID-19 vaccine strategy, prioritisation of population groups

The prime minister directed that a time-bound plan be laid out for speedy regulatory clearances and timely procurement for early rollout of the vaccination programme

As race to COVID-19 vaccine heats up, a look at major jabs, development and clinical trials underway
India

As race to COVID-19 vaccine heats up, a look at major jabs, development and clinical trials underway

According to WHO, there are 48 COVID-19 vaccine candidates are undergoing clinical evaluation, of which eleven are at late-stage trials, whereas, 164 candidate vaccines are in preclinical evaluation

COVID-19 vaccine to reach 30 cr by July-Aug, says Harsh Vardhan; healthcare workers, people above 65 yrs priority
India

COVID-19 vaccine to reach 30 cr by July-Aug, says Harsh Vardhan; healthcare workers, people above 65 yrs priority

Stating that everything is being decided by experts with a scientific point of view, the Union health minister expressed confidence that the COVID-19 vaccine will be ready in the next three to four months